Home » Healthcare » Pharmaceuticals » Blood and Bone Marrow Cancer Treatment Market

Blood and Bone Marrow Cancer Treatment Market By Indication (Multiple Myeloma, Leukemia, Lymphoma and Others), By Therapy (Chemotherapy, Immunotherapy, Stem Cell Transplant and Radiotherapy) – Growth, Future Prospects & Competitive Analysis, 2019 – 2027

Summary
Table Of Content

Industry Outlook

The blood and bone marrow cancer treatment market is set to grow from US$ 38.8 billion in 2018 to US$ 74.9 billion by 2027 at a compound annual growth rate (CAGR) of 7.7% during the forecast period from 2019 to 2027. As per the research findings brought forward by Janssen Pharmaceutica N.V., approximately 900,000 people throughout the globe are diagnosed with blood cancer annually, which holds a share of 7% of all types of known cancer.

Access crucial information at unmatched prices!

Request your free sample report today & start making informed decisions powered by Credence Research!

Download Free Sample

Market Synopsis

Increasing prescription of immunosuppressive drugs for treating chronic infections and genetic mutations together are responsible for the growing incidence of lymphoma worldwide.

Lymphoma is leading the indications segment in the blood and bone marrow cancer treatment market. Hodgkin lymphoma and non-Hodgkin lymphoma are the two types prevalent worldwide. The important parameters responsible for its growing incidence throughout the globe are the increasing prescription of immunosuppressant drugs for treating chronic infections and genetic mutations. Leukemia occurs when the DNA of immature white blood cells gets damaged due to exposure to ionizing radiation, hazardous chemicals, smoking, etc. The prevalence rate varies according to ethnicity, with a higher occurrence in men in comparison to the female population worldwide.

A strong product pipeline will ensure rampant market growth for immunotherapy during the forecast period.

Chemotherapy is dominating the therapy segment of the blood and bone marrow cancer treatment market. The primary factor responsible for its increasing prescription worldwide is the availability of its generic version at an affordable cost, drastically reducing the healthcare burden on ailing patients. Oncologists frequently use them in combination therapy, either with radiotherapy or immunotherapy, to treat patients showing resistance to first-line drug therapy. Immunotherapy is set to register impressive growth in the near future on account of its promising product pipeline, which will be commercially available during the forecast period.

Rising prevalence of blood cancer and an affordable reimbursement scenario for the medicines employed in its treatment together drive the market’s growth in North America.

North America, with a market share of 34.6%, currently reigns over the regional segment for the blood and bone marrow cancer treatment market. The chief contributing factor to its market dominance is the rising prevalence of blood cancer. According to Leukemia and Lymphoma Society (CDC) facts and figures, approximately every 3 minutes, one person in the U.S. is diagnosed with blood cancer. In 2019, in the United States, approximately 176,200 people were diagnosed with either leukemia, myeloma, or lymphoma. Affordable reimbursement scenarios for the medicines employed in its treatment are another important factor that contributes to its regional market growth. Europe holds a share of 30.8%, primarily due to the supportive regulatory framework provided by the European Medical Agency for the development and sale of medication for the treatment of blood cancer. Asia Pacific represents 18.4% of the market share on account of rising public health awareness related to blood cancer and its treatment and developing healthcare infrastructure.

Historical and Forecast Period

This research report presents the analysis of each segment from 2017 to 2027, considering 2018 as the base year for the research. The compound annual growth rate (CAGR) for each of the respective segments is calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

The market is segmented by indication, therapy, and geography.

Pharmaceutical companies spearheading the blood and bone marrow cancer treatment market are Bristol-Myers Squibb & Company, AstraZeneca, Plc., Eli Lilly & Company, Johnson & Johnson Company, F.Hoffman La-Roche Ltd., Celgene, Inc., Merck & Co., Inc., Novartis AG, Varian Medical Systems, Inc., and Pfizer, Inc.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key questions are answered in this report.

Which pharmaceutical companies are providing medications for the treatment of blood and bone marrow cancer?
What are the drivers, opportunities, and restraints studied in the blood and bone marrow cancer treatment market?
What is the prevalence rate of different types of blood cancer?
What are the factors responsible for the large market share of chemotherapy?
What will be the market performance of Asia Pacific, the Middle East, Africa, and Latin America during the forecast period?

Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global BBMCT Market Portraiture
2.2. Global BBMCT Market, by Indication, 2018 (US$ Bn)
2.3. Global BBMCT Market, by Therapy, 2018 (US$ Bn)
2.4. Global BBMCT Market, by Geography, 2018 (US$ Bn)

Chapter 3. Blood and Bone Marrow Cancer Treatment (BBMCT) Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global BBMCT Market, by Key Players, 2018

Chapter 4. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Indication
4.1. Overview
4.2. Multiple Myeloma
4.3. Leukemia
4.4. Lymphoma
4.5. Others

Chapter 5. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Therapy
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Stem Cell Transplant
5.4. Radiotherapy
5.5. Pipeline Analysis
5.5.1. Phase III Drug
5.5.1.1. Eltrombopag
5.5.1.2. Avatrombopag
5.5.1.3. Hetrombopag
5.5.1.4. Omidubicel
5.5.1.5. Fedratinib
5.5.1.6. ATIR101
5.5.1.7. Pegylated Proline Interferon Alpha-2b
5.5.2. Tabular Representation of Phase II and I Pipeline Drugs

Chapter 6. Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market, by Geography
6.1. Overview
6.2. North America BBMCT Market Analysis, 2017– 2027
6.2.1. North America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America BBMCT Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe BBMCT Market Analysis, 2017 – 2027
6.3.1. Europe BBMCT Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific BBMCT Market Analysis, 2017 – 2027
6.4.1. Asia Pacific BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific BBMCT Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America BBMCT Market Analysis, 2017 – 2027
6.5.1. Latin America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa BBMCT Market Analysis, 2017 – 2027
6.6.1. MEA BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Celgene, Inc.
7.3. Bristol Myers Squibb & Company
7.4. Eli Lilly & Company
7.5. Johnson & Johnson Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis AG
7.9. Pfizer, Inc.
7.10. Varian Medical Systems, Inc.

List of Figures

FIG. 1 Blood and Bone Marrow Cancer Treatment (BBMCT) Market: Research Methodology
FIG. 2 BBMCT: Market Segmentation
FIG. 3 Global BBMCT Market, by Indication, 2018 (US$ Bn)
FIG. 4 Global BBMCT Market, by Therapy, 2018 (US$ Bn)
FIG. 5 Global BBMCT Market, by Geography, 2018 (US$ Bn)
FIG. 6 Attractive Investment Proposition: by Geography, 2018
FIG. 7 Competitive Analysis: Global BBMCT Market, by Key Players, 2018
FIG. 8 Global Multiple Myeloma Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 9 Global Leukemia Market for BBMCT, 2017– 2027 (US$ Bn)
FIG. 10 Global Lymphoma Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 11 Global Other Indication Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 12 Global Chemotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 13 Global Immunotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 14 Global Stem Cell Transplant Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 15 Global Radiotherapy Market for BBMCT, 2017 – 2027 (US$ Bn)
FIG. 16 U.S. BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 17 Canada BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 18 U.K. BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 19 Germany BBMCT Market, 2017– 2027 (US$ Bn)
FIG. 20 Rest of Europe BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 21 China BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 22 Japan BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 23 Rest of Asia Pacific BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 24 Brazil BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 25 Mexico BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 26 Rest of Latin America BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 27 GCC BBMCT Market, 2017 – 2027 (US$ Bn)
FIG. 28 Rest of MEA BBMCT Market, 2017 – 2027 (US$ Bn)

List of Tables

TABLE 1 Global Blood and Bone Marrow Cancer Treatment (BBMCT) Market Portraiture
TABLE 2 Global BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 3 Global BBMCT Market , by Therapy, 2017 – 2027 (US$ Bn)
TABLE 4 Global BBMCT Market, by Geography, 2017 – 2027(US$ Bn)
TABLE 5 North America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 6 North America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 7 North America BBMCT Market, by Country, 2017 – 2027 (US$ Bn)
TABLE 8 Europe BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 9 Europe BBMCT Market, by Therapy, 2017 – 2027(US$ Bn)
TABLE 10 Europe BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 11 Asia Pacific BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 12 Asia Pacific BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 13 Asia Pacific BBMCT Market, by Country/Region, 2017– 2027 (US$ Bn)
TABLE 14 Latin America BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 15 Latin America BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 16 Latin America BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 17 Middle East and Africa BBMCT Market, by Indication, 2017 – 2027 (US$ Bn)
TABLE 18 Middle East and Africa BBMCT Market, by Therapy, 2017 – 2027 (US$ Bn)
TABLE 19 Middle East and Africa BBMCT Market, by Country/Region, 2017 – 2027 (US$ Bn)
TABLE 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Celgene, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 Bristol Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 Johnson and Johnson Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

FrequentlyAsked Questions

What is the size of Blood and Bone Marrow Cancer Treatment Market?

The market for Blood and Bone Marrow Cancer Treatment Market is expected to reach US$ 74.9 Bn in 2027.

What is the Blood and Bone Marrow Cancer Treatment Market CAGR?

The Blood and Bone Marrow Cancer Treatment Market is expected to see significant CAGR growth over the coming years, at 7.7% .

What is the Forecast period considered for Blood and Bone Marrow Cancer Treatment Market?

The report is forecasted to 2019-2027.

What is the base year considered for Blood and Bone Marrow Cancer Treatment Market?

The base year of this report is 2018.

Who are the major players in this market?

AstraZeneca, Plc.,Celgene, Inc.,Bristol Myers Squibb & Company,Eli Lilly & Company,Johnson & Johnson Company are some of the major players in the global market.

Purchase Options

Single User

$3699

Multi User

$4699

Custom Report

$6699

Request Free Sample

Have a question?

Don’t settle for less – trust Mitul to help you find the best solution.

Call: +91 6232 49 3207

EMAIL MITUL

Report delivery within 24 to 48 hours

– Other Info –

–What people say?-

I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.

Jana Schmidt
CEDAR CX Technologies

– Connect with us –